TG6050

AXP000096.1 · Oncolytic virus

Platform
vaccinia virus (Copenhagen)
Originator
Transgene
Sponsor
Transgene

Names

NameTypeSource
TG6050preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
Copenhagen
Replication
conditionally replicating
Modifications
thymidine kinase (J2R) deleted; further deletions not confirmed
Transgenes
IL12A, IL12B, anti-CTLA-4 antibody
Route
intravenous
Source
evidence

Cross-references

NCI Thesaurus
C200558

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05788926A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)TerminatedPhase 12023-04-052025-06-2322Non-small Cell Lung Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39060022TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment.Journal for immunotherapy of cancer2024cited by trial NCT05788926

Notes

Intravenous oncolytic vaccinia carrying IL-12 and a full-length anti-CTLA-4 antibody; phase 1 in NSCLC (NCT05788926) terminated 2025.

How to cite

TG6050 (AXP000096.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000096.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.